Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer

Singh, Amisha; Osbourne, Appledene S; Koshkin, Vadim S.

doi:10.1007/s11864-023-01113-z

Cited by 5 publications

(2 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Perioperative immunotherapy is increasingly used for the management of resectable solid tumors [65][66][67][68]. Potential advantages of the early introduction of ICIs include the enhancement of the anti-tumor immune response due to a higher tumor antigen load before resection, a greater chance of downstaging the tumor and increasing the chances of complete resection, early reversal of an immunosuppressed environment, and improved tolerability in treatment-naïve patients [69][70][71].…”

Section: Immune Checkpoint Inhibitors For Locally Advanced Resectable...mentioning

confidence: 99%

Immunotherapy for Thymomas and Thymic Carcinomas: Current Status and Future Directions

Rajan,

Sivapiromrat,

McAdams

2024

Cancers

View full text Add to dashboard Cite

Thymic epithelial tumors are a histologically diverse group of cancers arising from the epithelial compartment of the thymus. These tumors are characterized by a low tumor mutation burden, a lack of actionable genomic changes, and, especially with thymomas, defects in immune tolerance. Surgery is the mainstay of the management of resectable disease, whereas advanced, unresectable tumors are treated with platinum-based chemotherapy. Disease recurrence can occur months to years after frontline treatment. Although several options are available for conventional treatment of recurrent thymic tumors, response rates are generally low, and treatment-related toxicity can affect quality of life. A subset of patients benefit from biologic therapies, but there remains an unmet need for the development of new treatments. Immune checkpoint inhibitors are safe, clinically active, and have contributed to an improvement in survival for patients with a wide variety of cancers. However, the application of these revolutionary treatments for thymic cancers is limited to their use for the management of recurrent thymic carcinoma because of the risk of immune toxicity. In this paper, we review the current uses of immunotherapy for the management of thymic epithelial tumors and highlight potential strategies to improve safety and broaden the application of these treatments for patients with thymic cancers.

show abstract

Section: Immune Checkpoint Inhibitors For Locally Advanced Resectable...mentioning

confidence: 99%

Immunotherapy for Thymomas and Thymic Carcinomas: Current Status and Future Directions

Rajan,

Sivapiromrat,

McAdams

2024

Cancers

View full text Add to dashboard Cite

show abstract

“…Bladder cancer (BC) ranks among the 10 ten malignant tumors around the world; it can be classified into muscle‐invasive BC (MIBC) and non‐muscle‐invasive BC (NMIBC) depending on the depth of tumor invasion (Richters et al., 2020 ). With the introduction of immune checkpoint inhibitors (ICIs), previous clinical studies have demonstrated that preoperative chemotherapy combined with immunotherapy could be an effective treatment option for BC patients (Singh et al., 2023 ).…”

Section: Introductionmentioning

confidence: 99%

Electrocardiographic characteristics of bladder cancer patients receiving preoperative chemotherapy combined with immunotherapy

Chen,

Jia,

Zheng

et al. 2024

Noninvasive Electrocardiol

View full text Add to dashboard Cite

ObjectivePatients treated with preoperative chemotherapy and immunotherapy for bladder cancer may be at increased risk of cardiotoxicity and electrophysiological abnormalities. This study aimed to analyze their electrocardiographic (ECG) alterations.MethodsPatients with bladder cancer who were hospitalized and receiving tislelizumab plus nab‐paclitaxel (TnP) were enrolled prospectively. ECG, cardiac biomarkers, and echocardiography were performed at baseline and the end of TnP.ResultsA total of 60 patients (76.7% males), including 30 muscle‐invasive and 30 non‐muscle‐invasive bladder cancer, received three or four cycles of TnP, respectively. Hypertension was the commonest comorbidity (41.7%), and 25 patients (41.7%) were prescribed cardiovascular drugs. In comparison with baseline characteristics, cardiac troponin I (cTnI) and N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) were within normal ranges after TnP. However, echocardiographic parameter of left ventricular ejection fraction slightly decreased after TnP (62.81 ± 3.81% to 61.10 ± 4.37%, p = .011). The incidence of abnormal ECG increased from 65.0% at baseline to 76.7%, of which only a higher prevalence of fragmented QRS (fQRS) was observed (33.3% to 50.0%, p = .013; mainly in inferior leads). ECG parameters of QT dispersion (QTd) were prolonged significantly after the regimen (39.50 ± 11.37 to 44.20 ± 15.85 ms, p = .019).ConclusionIn bladder cancer patients receiving preoperative chemotherapy combined with immunotherapy, the main ECG abnormality was fQRS and QTd, with relatively normal cardiac biomarkers and echocardiographic parameters. Regular ECG screening should be carried out carefully to detect potential cardiotoxicity in the long‐term follow‐up.

show abstract

Advancements in neoadjuvant immune checkpoint inhibitor therapy for locally advanced head and neck squamous Carcinoma: A narrative review

Li,

Luo,

Jiang

et al. 2024

International Immunopharmacology

View full text Add to dashboard Cite

Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer

Cited by 5 publications

References 52 publications

Immunotherapy for Thymomas and Thymic Carcinomas: Current Status and Future Directions

Immunotherapy for Thymomas and Thymic Carcinomas: Current Status and Future Directions

Electrocardiographic characteristics of bladder cancer patients receiving preoperative chemotherapy combined with immunotherapy

Advancements in neoadjuvant immune checkpoint inhibitor therapy for locally advanced head and neck squamous Carcinoma: A narrative review

Contact Info

Product

Resources

About